Glenmark Pharmaceuticals reported a strong performance for the March quarter and the full year ended March 31, 2026, with double‑digit revenue growth and improved profitability across key markets. Consolidated revenue for Q4 FY26 rose 15.8% year‑on‑year to INR 37,706 million, while EBITDA stood at INR 7,626 million, translating into a margin of 20.2%. Profit after tax (PAT) for the quarter came in at INR 3,013 million, with a PAT margin of 7.6%.
For FY26, Glenmark’s consolidated revenue increased 27.5% to INR 169,825 million. The company reported EBITDA of INR 45,724 million, with an EBITDA margin of 26.9%, and PAT of INR 13,620 million, implying a full‑year PAT margin of 7.8%.
Commenting on the performance, Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd., said, “FY26 has been a defining year in Glenmark’s evolution. We delivered strong business performance while making meaningful progress against the strategic priorities that will shape our future.” He added that the landmark AbbVie partnership “validated the strength of our innovation capabilities and the global relevance of our science,” while differentiated launches in respiratory and other core therapies underscored the company’s expertise in its focus areas.
During the year, Glenmark’s innovation subsidiary, IGI, secured a landmark global licensing deal with AbbVie for ISB 2001, developed on its proprietary BEAT protein platform, for oncology and autoimmune diseases. The agreement includes an upfront payment of USD 700 million, a potential total deal value of USD 1.925 billion and tiered double‑digit royalties on net sales, with Glenmark leading commercialization across emerging markets.
Glenmark also strengthened its India business, which grew at about 1.5 times the Indian Pharmaceutical Market in secondary sales, making it the second fastest‑growing company among the top 15, as per IQVIA. Differentiated launches such as TEVIMBRA and BRUKINSA in oncology, Nebzmart GFB Smartules and Glenmark Airz FB Smartules in respiratory, and GLIPIQ in diabetes further reinforced its presence in chronic therapies.
Globally, the company expanded its respiratory and dermatology footprint, with RYALTRIS recording over 50% growth in secondary sales across commercial markets and securing approvals and launches in China, Thailand and the US. Glenmark also entered branded dermatology in Europe with the EU approval and UK launch of WINLEVI.
“We are building an organization that combines the scale and resilience of a global pharmaceutical business with the scientific ambition of an innovation‑driven organization amidst the evolving global landscape,” Saldanha said. “As we look ahead, we remain focused on disciplined execution, differentiated science, and creating greater impact for patients around the world.”
